Skip to main content

CORRECTION article

Front. Immunol., 05 August 2022
Sec. Cancer Immunity and Immunotherapy
Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.970322

Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression

This article is a correction to:

  1. Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression

    1. Read original article
Ana Micaela Carnaz SimesAna Micaela Carnaz Simões1Morten Orebo HolmstrmMorten Orebo Holmström1Pia AehnlichPia Aehnlich1Anne RahbechAnne Rahbech1Marlies J. W. PeetersMarlies J. W. Peeters1Aneta Radziwon-BalickaAneta Radziwon-Balicka1Carlos ZamoraCarlos Zamora2Tobias Wirenfeldt KlausenTobias Wirenfeldt Klausen1Vibe SkovVibe Skov3Lasse KjrLasse Kjær3Christina Ellervik,,Christina Ellervik4,5,6Daniel El Fassi,Daniel El Fassi4,7Silvia VidalSilvia Vidal2Hans Carl HasselbalchHans Carl Hasselbalch3Mads Hald Andersen,Mads Hald Andersen1,8Per thor Straten,*Per thor Straten1,8*
  • 1Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark
  • 2IIB-Sant Pau- Institut Rec. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  • 3Department of Hematology, Zealand University Hospital, Roskilde, Denmark
  • 4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • 5Department of Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
  • 6Department of Data and Innovation Support, Region Zealand, Sorø, Denmark
  • 7Department of Hematology, Rigshospitalet University Hospital, Copenhagen, Denmark
  • 8Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

A Corrigendum on:
Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression.

Carnaz Simões AM, Holmström MO, Aehnlich P, Rahbech A, Peeters MJ, Radziwon-Balicka A, Zamora C, Wirenfeldt Klausen T, Skov V, Kjær L, Ellervik C, Fassi DE, Vidal S, Hasselbalch HC, Andersen MH and thor Straten P (2022) 13:866610. doi: 10.3389/fimmu.2022.866610

In the published article, there was an error in the author list, and author Marlies J. W. Peeters was erroneously omitted. The corrected author list appears below.

Ana Micaela Carnaz Simões1, Morten Orebo Holmström1, Pia Aehnlich1, Anne Rahbech1, Marlies J. W. Peeters1, Aneta Radziwon-Balicka1, Carlos Zamora2, Tobias Wirenfeldt Klausen1, Vibe Skov3, Lasse Kjær3, Christina Ellervik4-6, Daniel El Fassi4,7, Silvia Vidal2, Hans Carl Hasselbalch3, Mads Hald Andersen1,8 and Per thor Straten*1,8

1Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Herlev University Hospital, Herlev, Denmark.

2 IIB-Sant Pau- Institut Rec. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

3Department of Hematology, Zealand University Hospital, Roskilde, Denmark.

4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

5Department of Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States.

6Department of Data and Innovation Support, Region Zealand, Sorø, Denmark.

7Department of Hematology, Rigshospitalet University Hospital, Copenhagen, Denmark

8Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: platelets, platelet-bound T cells, platelet-T cell aggregates, Myeloproliferative Neoplasms (MPN), CALR mutation, JAK2 mutation

Citation: Simões AMC, Holmström MO, Aehnlich P, Rahbech A, Peeters MJW, Radziwon-Balicka A, Zamora C, Klausen TW, Skov V, Kjær L, Ellervik C, Fassi DE, Vidal S, Hasselbalch HC, Andersen MH and Straten Pt (2022) Corrigendum: Patients with myeloproliferative neoplasms harbor high frequencies of CD8 T cell-platelet aggregates associated with T cell suppression. Front. Immunol. 13:970322. doi: 10.3389/fimmu.2022.970322

Received: 15 June 2022; Accepted: 11 July 2022;
Published: 05 August 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Simões, Holmström, Aehnlich, Rahbech, Peeters, Radziwon-Balicka, Zamora, Klausen, Skov, Kjær, Ellervik, Fassi, Vidal, Hasselbalch, Andersen and Straten. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Per thor Straten, per.thor.straten@regionh.dk

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.